Viking Therapeutics, Inc. (VKTX) Stock Analysis

Q: What is the VKTX stock price target?

Take-profit $36.05 (+19.9% upside). Prior stop was $27.96.

Q: What are the risks of investing in VKTX?

Concentration risk — Supplier: Ligand; DATA_ISSUE: analyst_target_implausible (raw $92.50 vs price $30.06 — ratio 3.1×). Rejected, falling back to technical TP.; Quality below floor (1.6 < 4.0); DATA_ISSUE: analyst_target_implausible (raw $92.50 vs price $30.06 — ratio 3.1×). Rejected, falling back to technical TP.; Quality below floor (1.6 < 4.0).

Q: Is VKTX overvalued or undervalued?

Viking Therapeutics, Inc. trades at a P/E of N/A (forward -7.7). TrendMatrix value score: 5.0/10. Overall verdict: Sell.

Q: What do analysts say about VKTX?

25 analysts cover VKTX with a consensus score of 4.2/5. Average price target: $93.

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Viking Therapeutics is a clinical-stage biopharmaceutical company developing metabolic and endocrine disorder treatments. Its lead candidate VK2735, a GLP-1/GIP dual agonist for obesity, is in Phase 3 trials (subcutaneous) with positive Phase 2 results for the oral formulation.... Read more

$30.17+19.9% A.UpsideScore 4.5/10#129 of 158 Biotechnology

Stop $27.96Target $36.05(resistance)A.R:R 0.0:1

Analyst target$92.50+206.6%18 analysts

$36.05our TP

$30.17price

$92.50mean

$125

Sell if holding. Engine safety override at $30.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 21%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.5/10, moderate confidence.

Passes 4/6 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Supplier: Ligand

DATA_ISSUE: analyst_target_implausible (raw $92.50 vs price $30.06 — ratio 3.1×). Rejected, falling back to technical TP.

Quality below floor (1.6 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-7.7

Mkt Cap$3.6B

EV/EBITDA—

Profit Mgn0.0%

ROE-47.3%

Rev Growth—

Beta0.82

DividendNone

Rating analysts25

Quality Signals

Piotroski F4/9

Options Flow

P/C0.53bullish

IV79%elevated

Max Pain$20-33.7% vs spot

Concentration Risks(10-K Item 1A)

HIGHSupplierLigand
10-K Item 1A: 'Our business is substantially dependent upon technology licensed from Ligand.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.015%0.75

Quality1.615%0.24

Growth5.015%0.75

Momentum2.210%0.22

Sentiment7.910%0.79

Insider Activity5.010%0.50

Peer Rank5.510%0.55

Technical Setup7.15%0.35

Risk Profile4.05%0.20

Catalyst3.25%0.16

Overall (Σ contributions)4.51

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Cash-burning (FCF negative)No competitive moatQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd

0.0

Obv

1.0

Ma Position

2.2

Rsi

3.0

Volume

4.7

Capitulation risk (RSI 26, below 200MA)Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.6%/30d) — pullback in uptrend, not confirmed weakness

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

News Activity

8.0

Earnings concerns: 0B/4M

GatesMomentum 2.2<4.5A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

26 · Oversold

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $28.82Resistance $36.79

Price Targets

$28

$36

A.Upside+19.5%

A.R:R0.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $92.50 vs price $30.06 — ratio 3.1×). Rejected, falling back to technical TP.

! Quality below floor (1.6 < 4.0)

! Momentum score 2.2/10 — below 4.5 minimum

Earnings

0/4 beats

Next Earnings2026-04-29 (nulld)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is VKTX stock a buy right now?

Sell if holding. Engine safety override at $30.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 21%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $27.96. Score 4.5/10, moderate confidence.

What is the VKTX stock price target?

Take-profit target: $36.05 (+19.9% upside). Prior stop was $27.96. Stop-loss: $27.96.

What are the risks of investing in VKTX?

Concentration risk — Supplier: Ligand; DATA_ISSUE: analyst_target_implausible (raw $92.50 vs price $30.06 — ratio 3.1×). Rejected, falling back to technical TP.; Quality below floor (1.6 < 4.0).

Is VKTX overvalued or undervalued?

Viking Therapeutics, Inc. trades at a P/E of N/A (forward -7.7). TrendMatrix value score: 5.0/10. Verdict: Sell.

What do analysts say about VKTX?

25 analysts cover VKTX with a consensus score of 4.2/5. Average price target: $93.

What does Viking Therapeutics, Inc. do?Viking Therapeutics is a clinical-stage biopharmaceutical company developing metabolic and endocrine disorder...